Pyrithyldione[1] (Presidon, Persedon) is a
psychoactive drug invented in 1949.[2]
An improved method of manufacture was patented by Roche in 1959.[3] It was used as a
hypnotic or
sedative and presumed to be less toxic than
barbiturates.[4] Today, this substance is no longer used.
Agranulocytosis was sometimes reported as
adverse effect.[5][6] Pyrithyldione is also a CYP2D6 inducer but is not as potent as glutethimide.[7] In studies, it increased the O-demethylation of codeine by 20%.
^US Patent 2090068 - 2,4-Dioxo-3,3-Dialkyl-Tetrahydropyridines and Process for the Manufacture of Same.
^Becker EL, Fabing HD, Hawkins JR (April 1949). "Presidon; a new sedative-hypnotic". Christ Hospital Medical Bulletin. 2 (4): 80–4.
PMID18144514.
^US patent 3019230, Hinderling R, Lutz AH, Schnider O, "Method for the preparation of 2,4-dioxo-tetrahydropyridines", issued 1962-01-30, assigned to Hoffmann-La Roche
^Ibáñez L, Ballarín E, Pérez E, Vidal X, Capellà D, Laporte JR (January 2000). "Agranulocytosis induced by pyrithyldione, a sedative hypnotic drug". European Journal of Clinical Pharmacology. 55 (10): 761–4.
doi:
10.1007/s002280050011.
PMID10663456.
S2CID25595314.
^Covner AH, Halpern SL (January 1950). "Fatal agranulocytosis following therapy with presidon (3,3-diethyl-2,4-dioxotetrahydropyridine) a new sedative hypnotic agent". The New England Journal of Medicine. 242 (2): 49–52.
doi:
10.1056/NEJM195001122420203.
PMID15399031.